Genentech agreed to pay Alector $100 million upfront for exclusive global rights to AL050, an engineered glucocerebrosidase (GCase) enzyme replacement approach aimed at Parkinson’s disease driven by GBA1-linked lysosomal dysfunction. Genentech will handle development, regulatory, manufacturing, and commercialization across indications, with Alector eligible for up to $1.17 billion in milestone payments. The deal also includes Alector’s brain delivery strategy—its proprietary brain carrier intended to cross the blood–brain barrier—positioning AL050 as a disease-mechanism bet rather than a dopamine-lifting therapy. The partnership is framed as supporting longer-term efforts in neurodegeneration, including follow-on use of capital for earlier-stage pipeline progress. For investors and strategists, the collaboration signals continued premium value placed on mechanistically targeted Parkinson’s therapies with differentiated delivery and patient biology constraints tied to GBA1 status.